Bevacizumab/Paclitaxel/Carboplatin D.R. Proprietary Clin. Gold Stand. for Trmt NSCLC
Posted 03-25-2010 at 03:15 PM by admin
Bevacizumab/Paclitaxel/Carboplatin Will Remain Decision Resources' Proprietary Clinical Gold Standard for the Treatment of Advanced Non-Small-Cell Lung Cancer
A Drug's Effect on Overall Survival is the Attribute that Most Influences Surveyed Oncologists' Prescribing Decisions in Advanced Non-Small-Cell Lung Cancer, According to a New Report from Decision Resources
WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018. While some therapies in development hold promise, most have less favorable efficacy, safety and tolerability and/or delivery features compared with bevacizumab/paclitaxel/carboplatin.
"The bevacizumab/paclitaxel/carboplatin regimen attains current and future gold-standard status based on its superior overall survival in patients with advanced non-small-cell lung cancer," stated Decision Resources Analyst Laila Siddique.
The new report entitled Advanced Non-Small-Cell Lung Cancer: Lack of Efficacious Therapies in Development Presents Opportunity for an Agent That Can Increase Overall Survival also finds that a drug's effect on overall survival is the attribute that most influences surveyed oncologists prescribing decisions in advanced non-small-cell lung cancer. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage over sales leader bevacizumab/paclitaxel/carboplatin on this attribute.
Read the rest of the article here.
Copyright © 1996-2010 PR Newswire Association LLC. All Rights Reserved.
A Drug's Effect on Overall Survival is the Attribute that Most Influences Surveyed Oncologists' Prescribing Decisions in Advanced Non-Small-Cell Lung Cancer, According to a New Report from Decision Resources
WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018. While some therapies in development hold promise, most have less favorable efficacy, safety and tolerability and/or delivery features compared with bevacizumab/paclitaxel/carboplatin.
"The bevacizumab/paclitaxel/carboplatin regimen attains current and future gold-standard status based on its superior overall survival in patients with advanced non-small-cell lung cancer," stated Decision Resources Analyst Laila Siddique.
The new report entitled Advanced Non-Small-Cell Lung Cancer: Lack of Efficacious Therapies in Development Presents Opportunity for an Agent That Can Increase Overall Survival also finds that a drug's effect on overall survival is the attribute that most influences surveyed oncologists prescribing decisions in advanced non-small-cell lung cancer. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage over sales leader bevacizumab/paclitaxel/carboplatin on this attribute.
Read the rest of the article here.
Copyright © 1996-2010 PR Newswire Association LLC. All Rights Reserved.
Total Comments 0
Comments
Recent Blog Entries by admin
- Research and Markets: Market of Paclitaxel Injection in China (08-20-2010)
- Relief for cancer patients may be 2,000 years old (08-20-2010)
- Melanoma Research Alliance Announces $5.2 Million in New Grants (08-20-2010)
- Melanoma Research Alliance Announces $5.2 Million in New Grants to Support Six Innova (08-20-2010)
- Breast cancer survivors don't need to be afraid of air travel: U of A study (08-20-2010)
